Impact of efavirenz on hormone-positive breast cancer survival in women living with HIV

AIDS. 2024 Jul 15;38(9):1439-1442. doi: 10.1097/QAD.0000000000003912. Epub 2024 Jun 27.

Abstract

Women living with HIV and breast cancer have poorer survival than HIV-negative women. Efavirenz-estrogen interactions are documented; however, the survival impact is unknown. Survival between women with estrogen-receptor positive breast cancer taking efavirenz (n = 38) and nonefavirenz regimens (n = 51) were compared. The 5-year overall-survival was 48.9% [95% confidence interval (CI) 33.0-72.2 and 51.1% (95% CI 34.0-76.8)] in the efavirenz and nonefavirenz groups, respectively suggesting efavirenz is unlikely driving poorer survival in women living with HIV and estrogen-receptor positive breast cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Alkynes*
  • Anti-HIV Agents* / therapeutic use
  • Benzoxazines* / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / mortality
  • Cyclopropanes* / therapeutic use
  • Female
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • HIV Infections* / mortality
  • Humans
  • Middle Aged
  • Survival Analysis

Substances

  • Benzoxazines
  • efavirenz
  • Cyclopropanes
  • Alkynes
  • Anti-HIV Agents